Cancer cells don’t just compete — they collaborate. A recent study published in Nature uncovered a surprising strategy of cooperative metabolism that tumors use to thrive in harsh environments. The researchers found that cancer cells can share nutrients by breaking down extracellular peptides through a process driven by the enzyme carnosine dipeptidase 2 (CNDP2).
Furthermore, by disrupting this nutrient-sharing system, the researchers successfully reduced tumor growth in mice.
The findings suggested that blocking this cooperative behavior could weaken tumors without harming healthy tissues, offering a novel and potentially less toxic approach to cancer therapy. This discovery also opens new possibilities for cancer treatments targeting tumor cooperation.
Image Credit: Komsan Loonprom/Shutterstock.com
Tumor Growth Mechanisms
For decades, cancer research has focused on how tumor cells compete for resources. However, recent studies suggest that cooperation also plays a crucial role in tumor survival and growth.
In nature, cooperation helps species survive extreme conditions—penguins huddle to stay warm, and herbivores graze in groups to escape predators.
Similarly, tumors face extreme conditions in the form of nutrient scarcity due to poor blood supply, forcing cancer cells to adapt. Scientists have long recognized that tumors manipulate their microenvironment to support survival, but the idea that cancer cells actively cooperate to share nutrients is relatively new.
Moreover, while previous research has explored how tumors hijack growth signals, the role of direct metabolic cooperation has remained largely unstudied.
Investigating Tumor Cell Cooperation
Understanding how tumors sustain themselves under nutrient-limited conditions is essential for developing more effective treatments. This study investigated how tumor cells collectively process and consume extracellular peptides, shedding light on a previously overlooked survival mechanism.
To understand how tumor cells cooperate to metabolize extracellular peptides, the researchers conducted a series of in vitro and in vivo experiments. First, they cultured lung cancer cells in nutrient-limited conditions and observed their growth patterns using high-throughput live microscopy.
The researchers genetically modified cancer cells by knocking out the CNDP2 gene, which encodes an aminopeptidase responsible for breaking down extracellular peptides into usable amino acids. They compared the growth of CNDP2-deficient cells with normal cancer cells to determine the enzyme’s role in cooperative metabolism.
Additionally, the study conducted metabolic tracing using gas chromatography-mass spectrometry to analyze how cells processed peptides. They also used competition assays to track the relative fitness of CNDP2-deficient cells versus normal tumor cells.
To confirm these findings in living organisms, they implanted genetically modified cancer cells into mouse models and treated them with bestatin, an aminopeptidase inhibitor. The mice were monitored for tumor growth over several weeks, with researchers assessing the impact of CNDP2 inhibition on cancer progression.
Major Findings
The researchers found that tumor cells depend on CNDP2 to break down extracellular peptides, which enables them to survive in nutrient-limited conditions. The study showed that when CNDP2 was inhibited, either genetically or using bestatin treatment, the tumor growth slowed down significantly. Notably, in mouse models, blocking CNDP2 led to a marked reduction in tumor size without major side effects.
The results also revealed that tumors with mutations in the gene KEAP1 (Kelch-like ECH-associated protein 1), linked to oxidative stress response, were particularly dependent on CNDP2-mediated cooperation.
Furthermore, patients with lung cancer and high CNDP2 expression had worse survival outcomes, suggesting a clinical link between this enzyme and aggressive tumor behavior. Despite its role in tumor metabolism, CNDP2 is rarely mutated in cancers, indicating that targeting this pathway could disrupt tumor growth without affecting healthy tissues.
The researchers also acknowledged some of the limitations of the study, such as the lack of clarity on the exact mechanism of CNDP2 secretion. They stated that further research is needed to determine how tumors spatially regulate their activity.
Additionally, the study primarily focused on lung cancer models, and it is unclear whether similar cooperative mechanisms occur in other cancer types. Future research could explore whether targeting CNDP2 is effective across different tumor environments.
A New Target For Cancer Therapy?
In conclusion, this study highlighted a novel way in which cancer cells cooperate to survive nutrient scarcity and identified CNDP2 as a promising target for future therapies.
The findings suggested that by disrupting this cooperation between tumor cells, researchers may be able to develop new treatments that selectively weaken cancer cells while sparing healthy tissues.
Furthermore, while more research is essential, these findings could lead to more effective strategies for slowing tumor growth and improving patient outcomes.
New Atlas Maps How Aging Breast Tissue Contributes to Cancer Risk